LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

MRK

115.22

+0.3%↑

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

MRK

115.22

+0.3%↑

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

MRK

115.22

+0.3%↑

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

MRK

115.22

+0.3%↑

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

MRK

115.22

+0.3%↑

Search

Celldex Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

32.19 1.71

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.33

Max

32.21

Galvenie mērījumi

By Trading Economics

Ienākumi

2.6M

-79M

Pārdošana

-60K

15K

EPS

-1.18

Peļņas marža

-524,566.667

Darbinieki

198

EBITDA

-3M

-84M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+59.09% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-330M

2.2B

Iepriekšējā atvēršanas cena

30.48

Iepriekšējā slēgšanas cena

32.19

Ziņu noskaņojums

By Acuity

50%

50%

162 / 342 Rangs Healthcare

Celldex Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Par Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat